N/A N=10 Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy
Vitiligo · Dermatology/Skin - Other
Primary: Molecular Changes From NB-UVB Therapy
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=39,374 Investigating Healthcare Disparities in Vitiligo
Vitiligo
Primary: Risk of Depression Within Patients With Vitiligo — 1412; 5395 Events
N/A N=75,771 Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
Vitiligo · Melanoma (Skin) · Nonmelanoma Skin Cancer
Primary: Number of New Onset Skin Cancer in Adult People Diagnosed With Vitiligo — 133; 812 Participants
N/A N=36,104 Mental Health Associations With Vitiligo
Vitiligo · Depressive Episode · Recurrent Depressive Disorder
Primary: Number of Participants With Depressive Episodes — 1018; 4007 Participants
N/A N=15 Photocil (Topical) for the Treatment of Vitiligo
Vitiligo
Primary: Percent Repigmentation — 48.5; 2.5 Percent Repigmentation
Phase 2 N=185 Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
Non-Segmental Vitiligo
Primary: Percent Change From Baseline in Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24 — -14.36; -21.96; -35.63; -33.96 Percent change from baseline — p=0.304
Phase 2 N=11 Topical Ruxolitinib for the Treatment of Vitiligo
Vitiligo
Primary: Percent Change in Vitiligo Area Severity Index (VASI) Score From Baseline to Week 20 — 23 percentage of change in VASI — p=0.02
Phase 2 N=15 Clinical Trial of Simvastatin to Treat Generalized Vitiligo
Vitiligo
Primary: Number of Participants With a Decrease in Vitiligo Area Scoring Index (VASI) Score — 0; 0 Participants
Phase 2 N=60 Evaluation of AMG 714 for Vitiligo
Vitiligo
Primary: Proportion of Participants Achieving a ≥ 35% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI35) at Week 24 — 0.150; 0.053 Proportion of…
N/A N=13 The Efficacy of Hand Narrow-Band Ultraviolet B (NBUVB) Versus Excilite Treatment in Vitiligo After Minigrafting on the Dorsal Hands
Vitiligo
Primary: Percent Repigmentation of Target Lesion — 0.21; 0.17 percentage of repigmentation
Phase 3 N=330 Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
Non-segmental Vitiligo
Primary: Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24 — 29.8; 7.4 percentage of…
Phase 3 N=344 Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
Non-segmental Vitiligo
Primary: Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24 — 30.9; 11.4 percentage of…
Phase 2 N=18 Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)
Vitiligo
Primary: Change in Pigmentation (Total and Individual Body Parts) Using the Vitiligo Area Scoring Index (VASI) — 0.00; 0.00; 0.00; 0.00 Change in VASI score from baseline
Phase 2 N=55 A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
Vitiligo
Primary: Change From Baseline in Total Body Vitiligo Area Scoring Index (T-VASI) at Week 48 — 6.58; 6.87; -3.43; -3.46 scores on a scale
Phase 2 N=171 A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
NonSegmental Vitiligo
Primary: Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24 — 2.29; -19.12; -17.78; -15.73 percent change — p=0.0015
Phase 2 N=327 Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
Non-segmental Vitiligo
Primary: Mean Change From Baseline in Vitiligo Area Scoring Index Score — -0.472; -0.271; -0.706; -1.145 score on a scale — p=0.7905
Phase 2 N=49 A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo
Nonsegmental Vitiligo With Genital Involvement
Primary: Percentage of Participants Achieving a Genital Vitiligo Noticeability Scale (VNS) of "4 - A Lot Less Noticeable" or "5 - No Longer Noticeable" at Week 48 — 27.0…
Phase 2 N=364 A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects
Active Non-segmental Vitiligo
Primary: Percent Change From Baseline in Central Read Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24 - Dose Ranging (DR) Period — -21.2; -21.2; -18.5; -14.6 Percent…
N/A N=50 Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
Vitiligo
Primary: Incidence of ≥80% Study Area Repigmentation — 0; 9 study areas — p=0.012
N/A N=6 Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study
Idiopathic Guttate Hypomelanosis
Primary: Efficacy Outcome — 2.31; 1.15 units on a scale
Phase 2 N=34 A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
Vitiligo
Primary: Mean Change From Baseline in Facial Depigmentation in the AOI (Area of Interest) Based on Canfield 2-D Photographic Analysis From Baseline to Week 24 — 2.0 score on a…
Phase 2 N=157 A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
Vitiligo
Primary: Percentage of Participants Treated With Ruxolitinib Cream Who Achieved a ≥ 50% Improvement From Baseline in Facial Assessment of the Vitiligo Area and Severity Index…
N/A N=25 PHNA, Efficacy of Tretinoin Cream on Post-phototherapy Hyperpigmentation
Vitiligo
Primary: The Degree of Hyperpigmentation at 12 Weeks — 56.8; 57.6; 51.0; 54.3 score on a scale — p=0.002
Phase 3 N=458 Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
Vitiligo
Primary: Time to Relapse (Defined as <F-VASI75) — NA; NA days — p=0.0414
N/A N=11 Blue Light Phototherapy
Grover's Disease · Psoriasis Vulgaris
Primary: Efficacy of Blue Light Therapy for Patients With Grover's Disease — 27; 6 lesion count
Phase 4 N=6 Can We Miss Pigmented Lesions in Psoriasis Patients?
Psoriasis · Melanoma · Non-melanoma Skin Cancer
Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants
Phase 2 N=60 A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)
Vitiligo
Primary: Percentage Change From Baseline in Chemokine (C-X-C Motif) Ligand 10 (CXCL10), an Immune Biomarker, at Week 4, Week 12, and Week 24 — -20.93; 8.13; -18.33; 21.13 percent…
Phase 2 N=60 Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
Alopecia Areata
Primary: Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -6.3; 2.3 score on a scale
N/A N=30,901 Healthcare Disparities in Alopecia Areata
Alopecia Areata
Primary: Likelihood of Depressive Episodes — 1217; 3576 Participants
Phase 2 N=20 Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
Acne Vulgaris
Primary: Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment — 0; 0 participants